Why the study?
Refractory arterial hypertension lacks blood pressure control despite multiple medications, prompting a review to elucidate neurohormonal and water-salt balance peculiarities to guide new antihypertensive therapy approaches.
Do sympatholytics and SGLT2 inhibitors improve blood pressure control in patients with refractory arterial hypertension?
Do sympatholytics and SGLT2 inhibitors improve blood pressure control in patients with refractory arterial hypertension?
This review highlights the role of sympathetic overactivity in refractory hypertension and suggests sympatholytics and SGLT2 inhibitors as potential therapeutic options.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for sympatholytics and SGLT2 inhibitors in refractory hypertension; randomized trials needed before practice change.
Refractory arterial hypertension is characterized by a lack of control of target blood pressure, despite the prolonged use >5 antihypertensive drugs with different mechanisms of action, including longacting diuretic chlorthalidone and the mineralcorticoid receptor antagonists (spironolactone or eplerenone). The review presents the results of clinical studies devoted the elucidating peculiarities of the neurohormonal status and water-salt balance in such patients and developing new approaches to antihypertensive drug therapy based on them. According to these studies, individuals with refractory hypertension differ from patients with resistant hypertension with the higher of sympathetic nervous system activity and the absence of an increased of intrathoracic fluid volume, which indirectly indicates a significant decrease in the intravascular fluid volume. In this regard, the review focuses on the data obtained in assessing the clinical efficacy of sympatholytics clonidine and reserpine in patients with resistant and refractory hypertension, as well as renal sodium-glucose co-transporter type 2 inhibitors, which suppress the sympathetic nervous system activity and can be used to overcome refractory hypertension in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Ob et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: